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Background
Adalimumab has been shown to be efficacious in child-
hood uveitis.
Materials and methods
We have switched to Adalimumab treatment eight
patients with chronic uveitis in whom, after 15–39
months of Infliximab infusions, recurrences of eye inflam-
mations were increasing. Four were males, four females;
in three cases uveitis was associated with JIA, in one with
early-onset sarcoidosis, in one with Behçet disease, while
three patients suffered from idiopathic uveitis. Adalimu-
mab was administered subcutaneously at the dosage of 24
mg/sq. meter every 2 weeks. Up to now (April 2008)
patients received from 18 to 24 injections each.
Results
At the onset of Adalimumab treatment in four patients
uveitis was active. One of them rapidly improved already
after the first injections, while another two progressively
recovered over the subsequent injections; in the fourth,
after an initial, partial remission, frequent flares were
observed and Adalimumab was discontinued. In the four
patients who were in remission at the onset of Adalimu-
mab, one of them maintained a durable remission, one
achieved a remission after 2 flares. One showed worsen-
ing activity, and an in another because of persistent
inflammation requiring pulses of methylprednisolone,
Adalimumab was discontinued. In 3 patients visual acuity
has already improved during Adalimumab treatment,
while in the remainder 5, either it deteriorated or
remained stable.
Conclusion
Our data suggest that Adalimumab may to be effective in
children with chronic uveitis even if they previously failed
another anti-TNF agent. However, long term follow-up
efficacy data still need to be established.
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